Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01936519 · ClinicalTrials.gov registry record · NA
Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.
A NA study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT01936519 is a NA study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 24 participants.
The verdict
NCT01936519, a NA study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will examine the renal sparing impact of implementing a strategy of conversion to everolimus from a calcineurin inhibitor based immunosuppressive protocol at 3 months post liver transplant
Interventions
- DRUG Arm A: Everolimus
- DRUG Calcineurin Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-12-16 |
| Est. Completion | 2019-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01936519
The ClinicalTrials.gov registry entry for NCT01936519 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arm A: Everolimus is the first listed.
NCT01936519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01936519 about?
NCT01936519 is a clinical study titled "Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.". This study will examine the renal sparing impact of implementing a strategy of conversion to everolimus from a calcineurin inhibitor based immunosuppressive protocol at 3 months post liver transplant
What is the current status of trial NCT01936519?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2013-12-16. Estimated completion is 2019-07-31.
What interventions are being tested in trial NCT01936519?
The interventions under investigation include: Arm A: Everolimus (DRUG), Calcineurin Inhibitor (DRUG).
Who is sponsoring clinical trial NCT01936519?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.